Core Viewpoint - AngioDynamics (ANGO) shares have increased by 26.5% in the past four weeks, closing at $7.65, with a potential upside indicated by Wall Street analysts' price targets suggesting a mean estimate of $13.33, representing a 74.3% upside [1] Price Targets and Analyst Consensus - The average price target for ANGO ranges from a low of $13 to a high of $14, with a standard deviation of $0.58, indicating a strong agreement among analysts about the stock's potential price movement [1][4] - The lowest estimate suggests a 69.9% increase from the current price, while the highest estimate points to an 83% upside [1] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism regarding ANGO's earnings prospects, as evidenced by a 30.2% increase in the Zacks Consensus Estimate for the current year, with two estimates moving higher and no negative revisions [5] - ANGO holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [5] Caution on Price Targets - While price targets are a popular metric, relying solely on them for investment decisions may not be prudent due to historical inaccuracies in predicting stock price movements [2][3][4] - Analysts often set optimistic price targets influenced by business relationships, which can lead to inflated estimates [3]

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:Kronos Worldwide, Inc. (KRO) : This titanium dioxide pigment company has seen the Zacks Consensus Estimate for its current year earnings increasing 12.9% over the last 60 days.First United Corporation (FUNC) : This bank holding company for First United Bank & Trust has seen the Zacks Consensus Estimate for its current year earnings increasing 9.1% over the last 60 days.PROG Holdings, Inc. (PRG) : This financial technology holding compan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | --- | |-----------------------------------------------------------------------|----------------------------------------------------------------------------------|---------------------------- ...

AngioDynamics, Inc. (ANGO) reported an adjusted loss per share of 6 cents for fourth-quarter fiscal 2024, against the year-ago quarter’s adjusted earnings per share (EPS) of 2 cents per share. However, the metric was narrower than the Zacks Consensus Estimate of a loss of 20 cents per share.On a pro-forma basis (excluding Dialysis and BioSentry businesses, the divested PICC, Midline, and tip location product portfolios and the discontinued RadioFrequency and Syntrax support catheter products), adjusted loss ...

Loading...Loading...Tuesday, AngioDynamics Inc (NASDAQ: ANGO) reported a fourth-quarter 2024 adjusted EPS loss of $0.05, compared to the consensus loss of $0.16.Fourth-quarter sales totaled $70.98 million, beating the analyst consensus of $70.89 million, according to data from Benzinga Pro.Pro forma net sales rose 1.9% to $71.1 million. Med Tech segment net sales were $29.3 million, up 11.3% year over year.Growth was driven by Auryon sales of $13.0 million, which increased 12.0%, NanoKnife disposable sales ...

Financial Data and Key Metrics Changes - Total pro forma worldwide revenue for Q4 FY 2024 was $71.1 million, representing a growth of approximately 2% year-over-year [7] - For the full fiscal year, revenue was $270.7 million, reflecting a growth of 5.3% [9] - Adjusted EBITDA for Q4 FY 2024 was $1.5 million, compared to $1.3 million in Q4 FY 2023 [35] - The company narrowed its adjusted loss per share to $0.05 in Q4 FY 2024 from $0.11 in the prior year [34] Business Line Data and Key Metrics Changes - Med Tech segment revenue grew 11% year-over-year in Q4 FY 2024, driven by Auryon and NanoKnife [7][27] - Med Device segment revenue declined approximately 4% in Q4 FY 2024, primarily due to reorganization impacts [8][31] - Auryon platform contributed $13 million in revenue during Q4, growing 12% compared to last year [28] - NanoKnife disposable revenue increased 18% year-over-year in Q4, with total NanoKnife sales up 30.5% for the full year [30] Market Data and Key Metrics Changes - Med Tech platforms comprised 41% of total revenue in Q4 FY 2024, up from 38% a year ago [27] - The total addressable market (TAM) for Med Tech has expanded from approximately $3 billion to roughly $10 billion since 2021 [10] Company Strategy and Development Direction - The company is focused on pursuing larger and faster-growing Med Tech markets, driving portfolio optimization, and deploying focused resource development [10][16] - The strategic transformation initiated in July 2021 has led to nearly doubling the revenue contribution from the Med Tech portfolio [18] - The transition to a fully outsourced manufacturing model is expected to generate approximately $15 million in annualized savings by fiscal 2027 [21] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of the Med Tech business, particularly with upcoming product launches and FDA approvals [41] - The company anticipates revenue for FY 2025 to be in the range of $282 million to $288 million, representing growth of 4.2% to 6.4% [38] - Management highlighted the importance of maintaining a strong balance sheet to support growth initiatives [36] Other Important Information - The company achieved a settlement in a long-standing IP litigation dispute, providing clarity and enabling a focus on innovation [22] - Nearly all products have received updated EU MDR approval, positioning the company well for international expansion [23] Q&A Session Summary Question: Guidance for next year, especially regarding Med Tech growth - Management indicated that some growth from the prostate indication is included in the guidance, but does not expect a significant spike post-indication [45][46] Question: Stability of AngioVac and efforts to maintain it - Management noted that AngioVac's stability is due to its unique design and targeted sales force training [53] Question: Reimbursement efforts for NanoKnife - Management is actively working on reimbursement pathways and expects to achieve significant value from NanoKnife through these efforts [58][60] Question: Differences in commercial strategies between the U.S. and Europe for AlphaVac - Management stated that while the fundamentals are the same, the U.S. market has progressed faster, and extensive training is being provided to the European team [64]

AngioDynamics Fourth Quarter and Full Year Earnings Presentation July 16, 2024 Forward-Looking Statements 2 Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunitie ...

AngioDynamics (ANGO) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to earnings of $0.02 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 70%. A quarter ago, it was expected that this medical device maker would post a loss of $0.14 per share when it actually produced a loss of $0.16, delivering a surprise of -14.29%.Over the last four quarters, the company ...

Exhibit 99.1 /namics PRESS RELEASE Investor Contact: AngioDynamics, Inc. Stephen Trowbridge, Executive Vice President & CFO (518) 795-1408 AngioDynamics Reports Fiscal Year 2024 Fourth Quarter and Full-Year Financial Results LATHAM, N.Y.--(BUSINESS WIRE)--Jul. 16, 2024-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patient ...

AngioDynamics, Inc. (ANGO) recently announced the European CE Mark approval for its AlphaVac F1885 System for the non-surgical removal of thrombi or emboli from the pulmonary arteries and the treatment of pulmonary embolism (PE).The application of the AlphaVac F1885 System in the non-surgical excision of thrombi or emboli from the venous vasculature is enhanced by the CE Mark approval, which is likely a significant step forward in improving patient care and safety for endovascular therapies in the EU, a mar ...